Cancers, Free Full-Text
Por um escritor misterioso
Descrição
Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researchers to characterize new therapeutic targets. Several studies have highlighted the role of histone deacetylase 6 (HDAC6) in various pathologies, including cancer. This protein effectively intervenes in cellular activities by its primarily cytoplasmic localization. In this review, we will discuss the molecular characteristics of the HDAC6 protein, as well as its overexpression in CML leukemic stem cells, which make it a promising therapeutic target for the treatment of CML.
Clinical Genitourinary Cancer, Journal
National Comprehensive Cancer Network - Home
Cancer free hi-res stock photography and images - Alamy
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers, Breast Cancer Research
Pancreatic Cancer Action Network – Research, Patient Support, Resources
Know the signs of cancer to catch it early
Home Page: Lung Cancer
Breast - Archives of Pathology & Laboratory Medicine
Prostate Cancer: Symptoms, Causes & Treatment
Download or order free information booklets
I Am Cancer Free! - Cancer Free Gift - Tapestry
Cancer - Wiley Online Library
European Journal of Cancer Prevention
MD Anderson Cancer Center: Cancer Treatment & Cancer Research Hospital